Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
While research suggests potential advantages, its equally important to acknowledge the limited data on long-term effects in humans and the FDAs categorization of ipamorelin as a 503A/503B drug
When you lift something too heavy or move the wrong way, the muscles in your lower back can stretch too far or tear slightly
Heres what else they have in common: You (generally) take them the same way
We have way more real-world data for Ozempic than we do for tirzepatide